NBT INC. Considers First Dividend and Share Buyback… Announces Third-Quarter Value-Enhancement Plan
Pushing to Enhance Corporate Value Based on Prospects for a Return to Profitability
Implementing stock price stabilization measures, including treasury stock buybacks and a 5 billion won liquidity injection
[Edaily Reporter Hyera Lee ] NBT INC.(236810)announced on the 15th that it will disclose a plan to enhance corporate value—including the cancellation of treasury shares, the purchase of new treasury shares, and its first dividend—during the third quarter. NBT INC. CI. (Photo = NBT INC.) The company is considering the cancellation of all 847,676 treasury shares it currently holds, additional treasury share repurchases using capital surplus, and its first cash dividend with a payout ratio exceeding the KOSDAQ average. In addition, the company plans to supply approximately 5 billion won in market liquidity by entering into liquidity provider (LP) agreements with securities firms and through on-market purchases by management, major shareholders, and strategic investors (SIs). To secure funds for shareholder returns, the company is also planning to hold an extraordinary general meeting of shareholders to propose resolutions to cover accumulated losses using capital surplus and to transfer retained earnings. The value-enhancement policy will be implemented based on improved financial performance. NBT INC. has projected standalone revenue of 107.9 billion won and operating profit of 2.1 billion won for this year. If these targets are met, revenue will increase by approximately 20% year-over-year, and the company will return to profitability after posting a loss of 6.48 billion won last year. The company expects improved profitability from the Addison Offer Wall and the launch of the Ad Exchange in the third quarter to drive this earnings recovery. An NBT INC. official stated, “We will narrow the gap between our corporate value and market valuation through a shareholder return roadmap linked to our growth.”
On the 3rd (local time), one day before the official opening of IFA 2026 in Berlin, Germany, foreign journalists and home appliance industry representatives toured the LGELECTRONICS exhibition hall. A…
Genome&Company(314130)is aiming for its third technology export deal, led by its next-generation antibody-drug conjugate (ADC) candidate, “GENA-120.” Although GENA-120 is still in the early clinical s…
Ildong Pharmaceutical stock trend on August 10. (Image: MP Doctor)
On September 2, Ildong Pharmaceutical emerged as one of the strongest performers among South Korean pharmaceutical and biotech st…